Indications and Surgeries for Chronic Pancreatitis

I. INDICATIONS FOR SURGERY

II. SURGICAL PROCEDURES

A. DRAINAGE OPERATIONS

1. Lateral Pancreaticojejunostomy (Modified Puestow / Partington-Rochelle Procedure)

• The classic drainage operation for large duct chronic pancreatitis
• The pancreatic duct is opened longitudinally along its entire length (head to tail), then anastomosed side-to-side to a defunctionalized Roux-en-Y limb of jejunum
• Indication: Dilated main pancreatic duct (>6 mm), diffuse disease
• Results are significantly worse when duct diameter is <6 mm (small duct disease)
• Lowest morbidity among all surgical options

B. RESECTION OPERATIONS

2. Pancreaticoduodenectomy (Whipple Procedure)

• Classic or pylorus-preserving variant
• Removes the pancreatic head, duodenum, and distal common bile duct - the so-called "pacemaker" region of the disease (Longmire)
• Provides pain relief in 65%-95% of patients
• Indications:
  • Small duct disease (large or small pancreatic head)
  • Disease limited to the head of the pancreas
  • Large inflammatory mass of the head where malignancy cannot be excluded
  • Associated biliary or duodenal obstruction
• Higher morbidity and mortality vs. drainage alone; surgical mortality <3% in high-volume centers; early complications (motility disruption, duct leaks) in up to 50%

3. Distal Pancreatectomy

• Removes the body and tail of the pancreas to the left of the splenic vein-portal vein confluence
• Indications:
  • Disease limited to the body and tail
  • High-grade ductal stricture in the body/tail causing upstream obstructive chronic pancreatitis
  • Disconnected left pancreatic remnant after severe acute pancreatitis with necrosis
• Used very selectively; strictures must be assessed for pancreatic cancer

C. COMBINED RESECTION + DRAINAGE OPERATIONS (DPPHR)

4. Beger Procedure (DPPHR - Classic)

• Technique: The pancreatic neck is transected. A subtotal resection of the pancreatic head is performed, coring out diseased tissue while preserving the duodenum and distal bile duct. The residual pancreas and bile duct are drained into a Roux-en-Y jejunal limb.
• Indications: Small duct chronic pancreatitis with a large, hypertrophic pancreatic head; also used selectively in pancreas divisum with small outflow tracts
• More diabetes risk than Frey, less than Whipple

5. Frey Procedure (DPPHR with Duct Drainage)

• Technique: Unlike the Beger procedure, the pancreatic neck is NOT transected. The pancreatic duct is opened longitudinally from head to tail. The pancreatic head is "cored out" (local head resection), leaving a thin rim of tissue adjacent to the duodenum and retropancreatic vessels. A Roux-en-Y jejunal limb is anastomosed to cover both the opened duct and the cored-out head.
• Indications: Small duct chronic pancreatitis with an enlarged head + dilated duct in body/tail (i.e., mixed pathology)
• Avoids dissection around portal/superior mesenteric veins - reduced bleeding risk
• Randomized trials vs. Beger show equivalent outcomes - similar complications, pain relief, and long-term quality of life

6. Berne Procedure

• A modification: pancreatic head resection without longitudinal duct incision, leaving a narrow layer of pancreatic tissue along the duodenum and retropancreatic vessels
• Avoids portal vein dissection

D. TOTAL PANCREATECTOMY WITH ISLET AUTOTRANSPLANTATION (TPIAT)

• The entire pancreas is removed. Islet cells are harvested and infused into the portal vein to maintain endocrine function.
• Indication: Intractable pain with a non-dilated pancreatic duct (small duct disease) where drainage procedures are not applicable, and where other operations have failed
• Patients must be accurately diagnosed with chronic pancreatitis before TPIAT, as imaging may not be definitive
• Best pain relief outcomes when performed before opioid dependence is established
• Increasingly performed; outcome data being collected via the Prospective Observational Study of TPIAT (TPIAT registry)

E. MINIMALLY INVASIVE APPROACHES

• Distal pancreatectomy
• Pancreatoduodenectomy
• Lateral pancreaticojejunostomy

Summary Table

Scoring Systems for Grading Severity of Acute Pancreatitis

1. RANSON'S CRITERIA (1974)

• <3 criteria: mild, uncomplicated disease, mortality <1%
• 3-4 criteria: ~15% mortality
• 5-6 criteria: ~40% mortality

• 6 criteria: ~100% mortality

• Severe pancreatitis = ≥3 criteria

2. APACHE II SCORE (Acute Physiology and Chronic Health Evaluation II)

• Severe pancreatitis = APACHE II score ≥8
• Advantages: Can be calculated on admission and repeated at any time - allows dynamic re-assessment; no need to wait 48 hours
• Limitations: Complex (15 variables); not specific to pancreatitis; age alone can inflate the score; many variables not routinely measured in non-critically ill patients
• PPV 43%, NPV 89% - similar to Ranson for ruling out severity

3. MODIFIED GLASGOW (IMRIE) SCORE

• Score ≥3 = severe pancreatitis
• Simpler than APACHE II; validated specifically for pancreatitis
• Like Ranson, requires 48-hour data

4. BISAP SCORE (Bedside Index for Severity in Acute Pancreatitis, 2008)

• Score ≥3 = severe pancreatitis with significantly increased mortality risk
• Advantages: Simple, bedside, calculable on admission, no 48-hour delay
• Predictive accuracy is comparable to APACHE II and Ranson
• BISAP score of ≥3 is associated with a >10-fold increase in mortality

5. CT SEVERITY INDEX (CTSI) - Balthazar Score

• CTSI ≥4 (or MCTSI ≥4) = high risk for severe disease
• CTSI correlates better with local complications (pseudocysts, abscesses) than with mortality
• Grade D or E: 54% local complication rate vs. 3.9% for grades A-C
• A Modified CTSI (MCTSI) adds extrapancreatic complications and simplifies the inflammation/necrosis scoring; found to be more useful clinically

6. REVISED ATLANTA CLASSIFICATION (RAC, 2012/2013)

• Organ failure is defined by a modified Marshall score ≥2 for respiratory, cardiovascular, or renal systems
• Mortality in severe acute pancreatitis: 36%-50%; extremely high with infected pancreatic necrosis
• Limitation: Final severity grade cannot be determined until ≥48 hours; limits use in the ED
• ~5% of presentations are severe; ~15% are moderately severe

7. HARMLESS ACUTE PANCREATITIS SCORE (HAPS)

1. Absence of peritonitis (no rebound tenderness or guarding)
2. Normal hematocrit
3. Normal serum creatinine

• 97% specific for mild disease - useful to safely identify patients who do not need intensive monitoring
• Not sensitive (misses some severe cases); used as a "rule-in mild" rather than "rule-in severe" tool

8. SIRS SCORE

• Pulse >90/min
• Temperature <36°C or >38°C
• WBC <4,000 or >12,000/mm³
• Respiratory rate >20/min or PaCO₂ <32 mmHg
• Simple, cheap, available at admission
• Studies show persistent SIRS after 48 hours predicts severe disease and organ failure
• SIRS is as good as complex scoring systems for early triage
• Incorporated into the BISAP score

Summary Comparison

Complications of Acute Pancreatitis

A. LOCAL COMPLICATIONS

1. Acute Peripancreatic Fluid Collection (APFC)

• Occurs within the first 4 weeks of interstitial edematous pancreatitis (no necrosis)
• Homogeneous, fluid-dense, no wall, no necrotic component, confined by fascial planes
• Occurs in 30-50% of cases of AP
• Contents are a mixture of inflammatory exudate and enzyme-rich secretions from disrupted side branches
• Most resolve spontaneously and do not require drainage
• Can track widely: lesser sac, retroperitoneum, mediastinum, small bowel mesentery

2. Pancreatic Pseudocyst

• Defined as an encapsulated fluid collection with a well-defined inflammatory wall, without significant necrosis, developing >4 weeks after onset of interstitial edematous pancreatitis
• Contains no solid/necrotic debris (if there is debris, the lesion is WON)
• Diagnosed on CT: well-circumscribed homogeneous fluid density with a complete wall
• Complications of pseudocysts (occur in ~10% of cases):
  • Infection - occurs in up to 25%; requires drainage (percutaneous or internal)
  • Rupture - into peritoneum causing pancreatic ascites/chemical peritonitis; into GI tract forming cystoenteric fistula; or into pleural space causing pancreaticopleural fistula
  • Bleeding - visceral artery erosion (splenic, gastroduodenal, middle colic arteries) by pancreatic elastase; leads to pseudoaneurysm, hemosuccus pancreaticus, or hemoperitoneum - life-threatening; treated with angiographic embolization
  • Mass effect - gastric outlet obstruction, biliary obstruction, duodenal obstruction, vascular compression

3. Necrotizing Pancreatitis

• Inflammation associated with necrosis of the pancreatic parenchyma, peripancreatic tissue, or both
• Affects ~20% of AP cases; associated with high morbidity and mortality
• On CECT: non-perfusing (hypo-enhancing) areas representing devitalized tissue
• Progresses through two stages based on timing:

a) Acute Necrotic Collection (ANC)

• Develops within 4 weeks of necrotizing pancreatitis
• Contains both fluid and solid necrotic debris (heterogeneous on CT)
• No defined wall; can be intrapancreatic or extrapancreatic
• Initially sterile but may become infected

b) Walled-Off Necrosis (WON)

• Develops >4 weeks after onset of necrotizing pancreatitis
• Mature, encapsulated collection of pancreatic and/or peripancreatic necrosis with a well-defined inflammatory wall
• Contents are heterogeneous (solid + liquid)
• Distinguishes from pseudocyst by the presence of solid necrotic debris
• Can be sterile or infected (infected WON = most dangerous local complication)

• Most important determinant of mortality in AP (mortality can reach 36-50% or higher)
• Suspected when there is gas within the necrotic collection on CT (pathognomonic) or rim enhancement
• Confirmed by CT-guided fine-needle aspiration (FNA) with Gram stain and culture
• Requires intervention: endoscopic necrosectomy (step-up approach), percutaneous drainage, or open surgical necrosectomy
• Commonest organisms: gut-derived bacteria (E. coli, Klebsiella, Enterococcus)

4. Pancreatic Abscess

• A circumscribed intra-abdominal collection of pus, usually in proximity to the pancreas, containing minimal or no pancreatic necrosis
• Arises from liquefaction of sterile necrosis or secondary infection of a pseudocyst
• Less severe than infected necrosis; lower mortality (~10-15%)
• Requires drainage

5. Pancreatic Fistula and Ascites

• Results from disruption of the main pancreatic duct or a side branch
• Internal fistula: enzyme-rich fluid tracks into adjacent structures
  • Pancreatic ascites (free fluid in peritoneum)
  • Pancreaticopleural fistula (most commonly left-sided pleural effusion)
  • Pancreaticoenteric fistula
• External fistula (pancreaticocutaneous): usually post-procedural
• Treatment: transpapillary stenting, surgical repair; octreotide (limited benefit)

6. Vascular Complications

a) Pseudoaneurysm

• Complicates <5% of severe AP
• Most commonly involves the splenic artery (also gastroduodenal, hepatic arteries)
• Caused by proteolytic digestion of vessel wall by pancreatic enzymes (especially elastase)
• Can rupture into pseudocyst, GI tract (hemosuccus pancreaticus), or free peritoneum
• Presents with sudden pain, hypotension, GI bleeding (hematemesis, melena, hematochezia)
• Treatment: emergency angiographic coil embolization (first line); surgery if embolization fails

b) Splenic Vein Thrombosis (Sinistral Portal Hypertension)

• Inflamed pancreatic tissue propagates clot into the splenic vein
• Causes left-sided (sinistral) portal hypertension
• Leads to gastric varices and risk of upper GI hemorrhage
• Generally managed expectantly unless bleeding occurs (splenectomy then curative)

c) Portal/Superior Mesenteric Vein Thrombosis

• Less common; can cause bowel ischemia if superior mesenteric vein involved
• Anticoagulation generally not routinely given unless symptomatic

7. Colonic/Bowel Complications

• Colonic necrosis/infarction - necrosis spreading from pancreas to adjacent transverse colon via transverse mesocolon; rare but life-threatening; requires resection
• Adynamic ileus - very common; due to retroperitoneal inflammation
• Gastric/duodenal obstruction - from inflammatory mass or large pseudocyst

8. Abdominal Compartment Syndrome (ACS)

• Increasingly recognized in severe AP managed with aggressive fluid resuscitation
• Defined as sustained intraabdominal pressure >20 mmHg + new organ dysfunction
• (Normal IAP = 5-7 mmHg; maximum normal = 12 mmHg)
• Diagnosed by bladder pressure measurement
• Management: diuresis, dialysis, bowel decompression; ultimately surgical decompression (midline laparotomy) if organ failure persists

B. SYSTEMIC COMPLICATIONS

1. Pulmonary Complications (Most Common Systemic Complication)

• Pleural effusion: enzyme-rich exudate, typically left-sided; indicates severe disease
• Atelectasis and pneumonia: from diaphragmatic splinting and immobility
• Acute Respiratory Distress Syndrome (ARDS): caused by circulating phospholipase A₂ and inflammatory mediators damaging the alveolar-capillary membrane; PaO₂ <60 mmHg; requires mechanical ventilation; associated with high mortality
• Pulmonary complications are present in up to one third of severe AP cases

2. Cardiovascular Complications

• Hypovolemia and hypotension: from massive "third-space" sequestration of fluid (up to 6+ liters) into retroperitoneum and bowel
• Shock: distributive (inflammatory) + hypovolemic
• Pericardial effusion
• Non-specific ST-T wave changes on ECG
• Sudden death (rare; due to myocardial depressant factor released from pancreas)

3. Renal Complications

• Acute kidney injury (AKI): from hypovolemia, hypotension, inflammatory mediators; oliguria and azotemia are early signs
• Renal artery/vein thrombosis (rare)
• Persistent AKI requiring dialysis is a marker of severe disease and is associated with increased mortality

4. Hematological Complications

• Hemoconcentration: Hematocrit >44% on admission predicts pancreatic necrosis
• Disseminated Intravascular Coagulation (DIC): consumption of clotting factors; associated with hemorrhagic pancreatitis and infected necrosis; life-threatening

5. Metabolic Complications

• Hyperglycemia: destruction of beta-cell islets; may be transient or permanent
• Hypocalcemia: calcium is "consumed" by saponification (calcium soap formation) in areas of fat necrosis; severe hypocalcemia (<7 mg/dL) is an independent predictor of severity and mortality
• Hypertriglyceridemia: may both cause and result from AP
• Metabolic encephalopathy (Pancreatic encephalopathy)
• Purtscher's retinopathy: sudden blindness caused by fat emboli/microthrombi in retinal vessels; rare but recognized complication

6. GI Hemorrhage

• Peptic ulcer disease - from stress and reduced mucosal protection
• Erosive gastritis - from systemic inflammatory response
• Variceal hemorrhage - secondary to splenic/portal vein thrombosis
• Hemosuccus pancreaticus - bleeding into the main pancreatic duct from a pseudoaneurysm; presents as intermittent upper GI bleeding

7. Central Nervous System

• Pancreatic encephalopathy: confusion, disorientation, agitation; mechanism involves circulating lipase, fat emboli, and cytokines affecting the brain
• Fat emboli
• Alcohol withdrawal syndrome (in alcohol-related AP)

8. Fat Necrosis

• Intra-abdominal saponification: calcium soap deposits at sites of fat necrosis (accounts for hypocalcemia)
• Subcutaneous fat necrosis: panniculitis presenting as tender red skin nodules, usually on the legs; rare but pathognomonic of severe pancreatitis
• Bone marrow fat necrosis (very rare)

Summary of Local Complications by Timing

Role of Surgery in Acute Pancreatitis

I. GENERAL PRINCIPLES

1. Infection - infected retroperitoneal collections must be drained (basic surgical principle)
2. Instability - clinical deterioration unresponsive to maximal ICU support mandates intervention
3. Intransigence - patients who fail to recover despite adequate non-operative therapy (ongoing pain, fever, food intolerance, persistent leukocytosis)

• Necrosis to liquefy and demarcate clearly from viable tissue (reducing bleeding and loss of functional pancreas)
• Spontaneous resolution of some collections
• The inflammatory response to partially settle
• Formation of a defined capsule (WON) that facilitates safer debridement

II. SPECIFIC INDICATIONS FOR SURGERY IN ACUTE PANCREATITIS

1. Infected Pancreatic Necrosis / Infected Walled-Off Necrosis (WON)

• Infection of necrotic pancreatic or peripancreatic tissue is the single most important determinant of mortality in AP
• Suspected when CT shows gas within the necrotic collection (pathognomonic) or clinical deterioration (fever, rising WBC, organ failure)
• Confirmed by CT-guided fine-needle aspiration (FNA) with Gram stain and culture
• Sterile necrosis causing persistent systemic illness (SIRS, organ failure) may also require drainage, as damage-associated molecular patterns (DAMPs) from sterile necrosis can trigger an immune response indistinguishable from infection

2. Abdominal Compartment Syndrome (ACS)

• Intra-abdominal pressure sustained >20 mmHg with new organ dysfunction
• Non-surgical measures tried first (diuresis, dialysis, bowel decompression, sedation)
• Surgical decompression via midline laparotomy is the definitive treatment

3. Intestinal Perforation or Colonic Necrosis

• Rare but catastrophic local complication
• Colonic infarction from peripancreatic spread via transverse mesocolon requires resection
• Bowel perforation requires emergency surgery

4. Uncontrolled Hemorrhage

• Pseudoaneurysm rupture: first-line is angiographic coil embolization; surgery required if embolization fails
• Massive intra-abdominal or GI hemorrhage not responding to angiography

5. Abdominal Catastrophe

• Bowel obstruction (gastric outlet or duodenal) not amenable to endoscopic relief
• Free perforation into the peritoneal cavity

6. Definitive Biliary Surgery (Cholecystectomy) in Gallstone Pancreatitis

• Laparoscopic cholecystectomy should be performed in all patients after an episode of gallstone pancreatitis
• Mild pancreatitis: Same-admission cholecystectomy is preferred. The PONCHO trial (Netherlands, 266 patients) showed same-admission cholecystectomy reduced recurrent gallstone-related complications by 72% compared with interval cholecystectomy (5% vs. 17% at 6 months, p=0.002), with a very low complication rate
• Severe pancreatitis: Cholecystectomy deferred until all pancreatic/peripancreatic collections are fully resolved (usually within 3 months)
• Unfit for surgery: Endoscopic biliary sphincterotomy reduces recurrence risk but is less effective than cholecystectomy for long-term biliary complications

III. THE STEP-UP APPROACH (CURRENT STANDARD OF CARE)

• Significantly fewer complications
• Less new-onset organ failure
• Lower mortality

Step 1: Percutaneous catheter drainage (image-guided)
           ↓ (if inadequate after 72 hours)
Step 2: Endoscopic transmural drainage (for WON accessible within 2 cm of stomach/duodenum)
           OR
        Video-Assisted Retroperitoneal Debridement (VARD)
           ↓ (if still failing)
Step 3: Minimally invasive necrosectomy (laparoscopic/retroperitoneoscopic)
           ↓ (last resort)
Step 4: Open surgical necrosectomy

IV. SPECIFIC SURGICAL AND INTERVENTIONAL TECHNIQUES

A. Percutaneous Catheter Drainage

• Performed under CT or ultrasound guidance by interventional radiology
• Preferred access: retroperitoneal, through the left flank, to avoid peritoneal contamination
• Serial catheter upsizing and intracatheter irrigation with saline/hydrogen peroxide used for semi-solid collections
• Disadvantage: risk of pancreaticocutaneous fistula
• Overall mortality in patients with necrotizing pancreatitis undergoing percutaneous drainage: ~17%

B. Endoscopic Transmural Drainage and Necrosectomy

• Best for mature WON located within 2 cm of the gastric or duodenal wall
• EUS-guided access: needle puncture through posterior stomach wall, cystogastrostomy created, balloon dilated, lumen-apposing metal stent (LAMS) or double pigtail stents placed
• Endoscopic necrosectomy: cystogastrostomy dilated to 15-20 mm, forward-viewing scope inserted into cavity, debris evacuated with forceps, snares, baskets and irrigation
• Typically requires multiple sessions (median 5 sessions over 21 days in one series)
• The PENGUIN trial showed endoscopic necrosectomy reduced composite major complications/death, fewer pancreatic fistulas, and less new organ failure vs. open/laparoscopic surgery
• TENSION trial: no difference in mortality/complications between endoscopic step-up and VARD step-up approaches, but endoscopic group had lower pancreatic fistula rates and shorter hospital stay

C. Video-Assisted Retroperitoneal Debridement (VARD)

• Minimally invasive retroperitoneal approach using the existing percutaneous drain tract as a guide
• Left flank incision extended to necrotic cavity; laparoscope inserted for direct visualization
• Drains left in situ for postoperative lavage
• Advantages: avoids peritoneal contamination, uses established drainage tract
• Disadvantages: limited visualization due to lack of insufflation; restricted operative field

D. Laparoscopic Transperitoneal Necrosectomy

• Pancreas accessed through gastrocolic ligament and transverse mesocolon
• Advantages: insufflation improves visualization; whole abdomen can be assessed; simultaneous cholecystectomy possible; robotic platform available for precision
• Disadvantages: risk of contaminating sterile peritoneal spaces; adhesion formation limits reoperation

E. Open Surgical Necrosectomy

• Indicated when:
  • All minimally invasive approaches have failed
  • Intestinal perforation or colonic necrosis requiring resection
  • Uncontrolled hemorrhage
  • Abdominal compartment syndrome requiring decompression
  • Necrosis too extensive or not accessible by other routes
• Technique: midline laparotomy or bilateral subcostal incision; retroperitoneum entered through lesser sac; necrotic tissue manually debrided with care to preserve viable tissue; drains placed for external drainage or continuous postoperative lavage; temporary abdominal closure may be used with planned re-look at 48-72 hours
• Postoperative course: patients kept intubated in ICU; massive third-space fluid losses expected; nasojejunal feeding initiated early
• Long-term complications: incisional hernia (~40%), pancreatic endocrine and exocrine insufficiency, pancreatic fistula, pseudoaneurysm

V. EARLY ERCP IN ACUTE BILIARY PANCREATITIS

• Indication: AP + concurrent cholangitis (urgent ERCP within 24-48 hours)
• NOT indicated in AP without cholangitis, even when biliary stones are suspected, as the stone usually passes spontaneously and ERCP may worsen pancreatitis
• If persistent cholestasis without cholangitis: MRCP to confirm retained stone first, then elective ERCP

VI. WHAT SURGERY IS NOT INDICATED FOR

• Sterile acute pancreatitis managed conservatively (vast majority of mild/moderate AP)
• Routine drainage of acute peripancreatic fluid collections (APFCs) - most resolve spontaneously
• Asymptomatic pseudocysts - expectant management; only intervene if symptomatic, enlarging, or complicated
• Early operation in the first week of severe AP (historically associated with >50% mortality)

Summary Table

Neoplasms of the Endocrine Pancreas and Management of Insulinoma

PART I: NEOPLASMS OF THE ENDOCRINE PANCREAS

A. FUNCTIONAL pNETs (Hormone-Secreting)

• Gastrinoma (ZES): Most located in the gastrinoma triangle (cystic duct base, D2-D3 junction, pancreatic neck); ~75% in duodenum, ~25% in pancreas; severe medically refractory peptic ulcer disease, gastroesophageal reflux, diarrhea; 20-30% associated with MEN1
• Glucagonoma: Necrolytic migratory erythema (pathognomonic rash), hyperglycemia, weight loss, glossitis, cheilitis, thromboembolism; often severe protein wasting requiring TPN before surgery
• VIPoma (Verner-Morrison syndrome): Profuse watery diarrhea, hypokalemia, achlorhydria - "WDHA" or "pancreatic cholera"; flushing, hypercalcemia
• Somatostatinoma: "Inhibitory syndrome" - diabetes mellitus, diarrhea/steatorrhea, cholelithiasis; location often peri-ampullary
• PPoma (Pancreatic polypeptidoma): Y cell origin; no clinical syndrome; tend to be large at diagnosis; incidental finding

B. NON-FUNCTIONAL pNETs

• Most common pNET overall
• Secrete pancreatic polypeptide, chromogranin A, or other markers in small quantities but without causing a hormone syndrome
• Present with mass-effect symptoms: abdominal/back pain, nausea/vomiting, obstructive jaundice, pancreatitis - or found incidentally on imaging
• Surgery recommended for lesions ≥2 cm; watchful waiting with serial imaging for lesions <2 cm (MEN1 patients: surveillance from age 13)

C. ASSOCIATED WITH MEN1

• Gastrinoma (~50%) - most common
• Insulinoma (10-30%)
• Nonfunctioning pNET / PPoma (20-55%)
• Glucagonoma (<3%)
• VIPoma (<1%)

PART II: MANAGEMENT OF INSULINOMA

1. CLINICAL FEATURES

1. Neuroglycopenic symptoms during fasting or exercise - confusion, behavioral change, blurred vision, seizures, coma (from brain glucose deprivation)
2. Documented hypoglycemia (blood glucose <50 mg/dL or <2.8 mmol/L at time of symptoms)
3. Symptomatic relief upon restoration of normoglycemia (glucose administration)

2. DIAGNOSIS

A. Biochemical Diagnosis

• 72-hour supervised fasting test - gold standard
  • Blood glucose, insulin, proinsulin, and C-peptide measured every 6 hours (more frequently as glucose drops)
  • Diagnostic criteria at time of hypoglycemia:
    • Blood glucose <55 mg/dL
    • Insulin ≥3 µU/mL (inappropriately elevated for the degree of hypoglycemia)
    • C-peptide ≥0.2 nmol/L (elevated, confirming endogenous insulin secretion)
    • Proinsulin ≥5 pmol/L
    • Beta-hydroxybutyrate ≤2.7 mmol/L
    • No sulfonylurea detected in urine/blood
• C-peptide testing differentiates endogenous (insulinoma) from exogenous insulin administration (factitious hypoglycemia): C-peptide is suppressed with exogenous insulin injection but elevated in insulinoma
• Some rare tumors secrete proinsulin rather than insulin

B. Tumor Localization

3. MEDICAL MANAGEMENT

• Bridge to surgery (while awaiting operation or to manage hypoglycemia)
• Long-term management in unresectable/metastatic disease or poor surgical candidates

A. Diazoxide (First-Line Medical Therapy)

• Mechanism: Acts on ATP-sensitive potassium (KATP) channels on β-islet cells → inhibits insulin secretion
• Dose: 50-300 mg/day orally (divided doses)
• Efficacy: Improves hypoglycemia in ~50% of patients with metastatic insulinoma
• Side effects: Fluid retention, peripheral edema, weight gain, congestive heart failure, renal dysfunction, hirsutism (with long-term use)
• Critical: Must be stopped at least 1 week before surgery - risk of severe intraoperative hypotension
• Hydrochlorothiazide is often added to counteract fluid retention

B. Somatostatin Analogues (SSAs) - Octreotide/Lanreotide

• Caution: Unlike other pNET syndromes, SSAs may paradoxically worsen hypoglycemia in insulinoma by inhibiting glucagon secretion (which provides counter-regulation). Used selectively.
• Only beneficial in the subset of insulinomas with high somatostatin receptor (SSTR) expression

C. Other Medical Options

• Phenytoin - inhibits insulin secretion
• Verapamil - calcium channel blocker; reduces insulin release
• Everolimus (mTOR inhibitor) - used in advanced/metastatic disease; reduces insulin secretion and tumor growth
• Streptozocin - cytotoxic to β cells; used in metastatic disease
• Frequent small meals - behavioral modification to prevent hypoglycemic episodes

4. SURGICAL MANAGEMENT (MAINSTAY OF TREATMENT)

Pre-operative Preparation

• Confirm diagnosis biochemically
• Localize tumor with CT/MRI/EUS
• Stop diazoxide ≥1 week pre-operatively
• IV glucose infusion maintained perioperatively to prevent hypoglycemia
• Intraoperative blood glucose monitoring throughout the procedure

Surgical Techniques

• Procedure of choice for small (<2 cm), superficial, benign insulinomas not adjacent to the main pancreatic duct
• Tumor is shelled out with a rim of normal pancreatic tissue
• Preserves maximum pancreatic parenchyma; low risk of exocrine/endocrine insufficiency
• Intraoperative ultrasound essential to define proximity to duct (risk of pancreatic fistula if duct is <2 mm from tumor)
• Excellent outcomes; cure rate approaching 100% for localized <2 cm insulinomas

• For tumors in the body and tail of the pancreas not amenable to enucleation (larger size, proximity to duct, multiple tumors)
• Usually spleen-preserving when possible (especially in benign disease)
• Can be performed laparoscopically or robotically

• For larger insulinomas in the head of the pancreas where enucleation is not safe
• Higher morbidity; reserved for when simpler procedures are not appropriate or when malignancy is suspected

• For tumors in the neck/proximal body; preserves both the head and a functional distal remnant

Intraoperative Adjuncts

• Intraoperative ultrasound (IOUS): Essential for locating non-palpable tumors and defining relationship to the pancreatic duct; sensitivity 70-95%
• Intraoperative rapid insulin assay: Aspiration of lesion + rapid insulin measurement can confirm identity of the lesion
• Palpation of entire pancreas (head, body, tail) through full mobilization

MEN1 and Multiple Insulinomas

• Patients with MEN1 may have multiple insulinomas throughout the pancreas
• Selective arterial calcium stimulation with hepatic vein insulin sampling used to identify the dominant functioning tumor
• May require subtotal (80%) pancreatectomy; risk of recurrence remains higher than sporadic insulinoma

5. LAPAROSCOPIC / MINIMALLY INVASIVE APPROACH

• Laparoscopic and robotic distal pancreatectomy and enucleation are now widely performed for insulinoma
• Advantages: reduced recovery time, less pain, shorter hospital stay
• IOUS can still be performed laparoscopically
• Conversion to open may be needed if the tumor cannot be localized

6. MANAGEMENT OF MALIGNANT INSULINOMA

• Diazoxide (first-line for hypoglycemia control)
• Everolimus (mTOR inhibitor) - shown to reduce hypoglycemic episodes and tumor growth
• Debulking surgery - palliative resection of primary and visible metastases to control hypoglycemia
• Liver-directed therapies for liver metastases: hepatic artery embolization (HAE), chemoembolization (TACE), radiofrequency ablation (RFA)
• Peptide receptor radionuclide therapy (PRRT) - Lutetium-177 dotatate (for tumors with sufficient SSTR expression)
• Chemotherapy - streptozocin + 5-fluorouracil or temozolomide + capecitabine (for high-grade pNETs)

7. OUTCOMES

Summary

Surgical Reconstruction After Whipple's Operation (Pancreaticoduodenectomy)

OVERVIEW OF THE OPERATION

1. Resection phase - removal of the pancreatic head, duodenum (entire), distal common bile duct, gallbladder, and distal stomach (classic) or proximal 2-3 cm of duodenum with pylorus preserved (PPPD)
2. Reconstruction phase - restoration of GI, biliary, and pancreatic continuity

1. Pancreatic anastomosis
2. Biliary anastomosis
3. Gastrointestinal anastomosis

VARIANTS OF PANCREATICODUODENECTOMY

A. Classic (Standard) Whipple

• Includes distal gastrectomy (antrectomy - removal of 40-50% of the distal stomach)
• Reconstruction uses a gastrojejunostomy (Billroth II-type)
• Applied when tumor involves the proximal duodenum, first portion of the duodenum, or peripyloric lymph nodes are involved

B. Pylorus-Preserving Pancreaticoduodenectomy (PPPD / Traverso-Longmire)

• The pylorus and proximal 2-3 cm of duodenum are preserved
• The right gastric artery and nerves of Latarjet must be preserved during duodenal division to maintain vascular supply and innervation
• Reconstruction uses a duodenojejunostomy
• Advantages: preserves gastric function, reduces bile reflux, avoids dumping syndrome, potentially improved nutrition
• Controversy: No proven difference in survival, margin positivity, or delayed gastric emptying compared with classic Whipple; should be used with caution for larger tumors involving the first portion of the duodenum

RECONSTRUCTION - SEQUENCE AND TECHNIQUES

• Retrocolic (through a defect in the transverse mesocolon, to the right of the middle colic vessels) - most common
• Antecolic (anterior to the transverse colon)
• Through the ligament of Treitz defect (used in robotic approach)

ANASTOMOSIS 1: PANCREATIC ANASTOMOSIS (Most Critical)

Option A: Pancreaticojejunostomy (PJ) - Most Common

• Most widely practiced technique
• Two-layer construction:
  • Outer layer (posterior): Interrupted 3-0 silk sutures between the pancreatic capsule and the seromuscular layer of the jejunum
  • A small enterotomy is made in the jejunum sized to match the pancreatic duct (not too large - size mismatch increases leak risk)
  • Inner duct-to-mucosa layer: Interrupted 5-0 monofilament absorbable sutures between the full-thickness pancreatic duct wall and the full-thickness jejunum
  • If a stent is placed, it is inserted into the duct and jejunum, secured with a single absorbable suture
  • Outer anterior layer: Interrupted 3-0 silk sutures to complete
• Pancreatic duct stent: A 5-Fr pediatric feeding tube trimmed to ~5 cm is used when: duct is not dilated, pancreas is soft, duct is eccentrically positioned. Stenting facilitates identification and construction of the duct-to-mucosa anastomosis and may reduce fistula rates in high-risk cases.
• The jejunum is approximated to the pancreas with firm but gentle pressure, following the curve of the needle to avoid tearing soft parenchyma

• The entire pancreatic stump is "dunked" or invaginated into the lumen of the jejunum like a sleeve
• Used by some centers particularly for soft pancreas with small duct where duct-to-mucosa anastomosis is technically difficult
• Two-layer technique: inner sutures fix the duct, outer sutures fix the capsule to the jejunum

• The pancreatic anastomosis is performed to a separate, isolated Roux-en-Y jejunal limb, completely separated from the biliary and GI limbs
• Theoretical advantage: isolates pancreatic secretions from the biliary limb; reduces activation of pancreatic enzymes by bile
• Used selectively in high-risk patients (soft pancreas, small duct)

Option B: Pancreaticogastrostomy (PG)

• The pancreatic stump is mobilized and brought through a defect in the posterior wall of the stomach into the gastric lumen
• Two-layer anastomosis: outer layer fixes capsule to seromuscular stomach; inner duct-to-mucosa layer with 5-0 sutures
• Some techniques use a pure invagination into the stomach

• The stomach has a naturally more alkaline environment (compared to jejunum activated with bile); pancreatic enzymes remain in zymogen (inactive) form
• Better blood supply to the stomach
• Easier to construct; more forgiving in soft pancreas

ANASTOMOSIS 2: BILIARY ANASTOMOSIS (Hepaticojejunostomy)

• Performed distal to the pancreaticojejunostomy on the same jejunal limb (typically 10-15 cm downstream), or on a separate Roux limb
• End-to-side hepaticojejunostomy using a single layer of interrupted absorbable sutures (4-0 or 5-0 monofilament)
• The common hepatic duct (CHD) cut end is anastomosed to the antimesenteric wall of the jejunum
• The jejunum is secured to the transverse mesocolon to minimize tension and reduce risk of internal hernia
• Adequate tissue on the hepatic duct edge is important; devascularization of the duct must be avoided
• If a percutaneous biliary drain is in place preoperatively, it is left traversing the anastomosis as a stent
• Note: If the gastrojejunostomy is placed too close to the hepaticojejunostomy (<20 cm), there is risk of retrograde reflux of gastric contents into the afferent limb causing cholangitis; the classic Whipple gastrojejunostomy is placed 20-30 cm distal to the hepaticojejunostomy

ANASTOMOSIS 3: GASTROINTESTINAL ANASTOMOSIS

A. Classic Whipple: Gastrojejunostomy

• The cut gastric remnant is anastomosed to the jejunum in a Billroth II (end-to-side) configuration, approximately 20-30 cm distal to the hepaticojejunostomy
• Can be performed antecolic (loop of jejunum brought in front of the transverse colon) or retrocolic (through the mesocolon) - both are acceptable, but antecolic is preferred at some centers
• Hand-sewn (two-layer) or stapled technique with equivalent outcomes
• The staple line from the gastric division is removed before the anastomosis

B. Pylorus-Preserving Whipple: Duodenojejunostomy

• End-to-side anastomosis between the preserved duodenal stump (2-3 cm distal to pylorus) and the jejunum, 10-15 cm downstream from the hepaticojejunostomy
• Single or two-layer anastomosis with absorbable sutures
• Before performing: check adequate vascular supply of the preserved duodenum and confirm nerves of Latarjet are intact; a Kelly clamp is used to gently stretch the pylorus
• Delayed gastric emptying (DGE): A significant complication seen in 20-30% of cases; rates do not differ significantly between classic Whipple and PPPD (controversial); antecolic position for the duodenojejunostomy may reduce DGE rates

SUMMARY OF THE RECONSTRUCTION (Standard)

Pancreatic remnant → (Pancreaticojejunostomy, end-to-side, duct-to-mucosa)
         ↓ (10-15 cm downstream on same jejunal limb)
Common hepatic duct → (Hepaticojejunostomy, end-to-side, interrupted sutures)
         ↓ (20-30 cm downstream)
Gastric remnant/Duodenum → (Gastrojejunostomy / Duodenojejunostomy, antecolic or retrocolic)

DRAINAGE

• Closed-suction drains (Jackson-Pratt or Blake) are placed adjacent to the pancreatic and biliary anastomoses
• Drain amylase is checked on postoperative day 1-3 before drain removal; elevated amylase (>3x serum upper limit) confirms POPF
• Some centers use selective drainage (no routine drains) with interventional radiology reserved for complications
• Nasogastric tube: Routinely removed the morning after surgery unless output is high
• Feeding jejunostomy: Placed selectively (30 cm distal to the gastrojejunostomy) in patients at high nutritional risk

POSTOPERATIVE COMPLICATIONS OF RECONSTRUCTION

VASCULAR RECONSTRUCTION (When Required)

• Tangential (lateral) venectomy + patch repair: Using a saphenous vein patch for small defects
• Segmental resection + primary end-to-end anastomosis: For segment resection <3 cm when the vein can be mobilized
• Interposition graft: Using the left internal jugular vein when a longer segment requires replacement and primary anastomosis is not possible
• Splenic vein preservation vs. ligation: Ligation of the splenic vein during PV/SMV reconstruction risks sinistral portal hypertension and gastric variceal bleeding

SPECIAL SCENARIOS IN RECONSTRUCTION

• Prior gastric bypass: Roux-en-Y reconstruction is used rather than the standard loop
• Narrow hepatic duct (<5 mm): Multiple interrupted fine sutures; consider stenting
• Very soft pancreas / non-dilated duct (<3 mm): Highest risk pancreas - consider duct stenting, consider PG, heightened drain surveillance
• Obliterated anatomy from prior surgery / inflammation: Modified approach; ensure tension-free anastomoses

Key Principles Summary

1. Three anastomoses are required: pancreatic, biliary, gastrointestinal
2. The pancreatic anastomosis (PJ or PG) is the most challenging and morbidity-driving step
3. Duct-to-mucosa PJ (two layers) is the most widely performed technique; PG has equivalent fistula rates
4. The hepaticojejunostomy is end-to-side with interrupted absorbable sutures; placed downstream from PJ
5. The GI anastomosis (gastrojejunostomy or duodenojejunostomy) is placed 20-30 cm downstream from hepaticojejunostomy
6. PPPD vs. classic Whipple: No proven survival difference; DGE rates similar; PPPD used with caution in large tumors
7. Drains are placed around the pancreatic and biliary anastomoses; drain amylase guides removal

Diagnosis and Management of Pancreatic Fistula Following Whipple's Procedure

DEFINITION

Drain output of any measurable volume of fluid with an amylase concentration greater than 3 times the upper limit of the institutional normal serum amylase value, on or after postoperative day 3.

INCIDENCE

• After pancreaticoduodenectomy (Whipple): 10-30% (clinically significant in 5-15%)
• After distal pancreatectomy: 20-30% (higher because the remnant stump is closed, not anastomosed)
• Overall mortality associated with POPF has declined from 10-40% (historical) to low single digits in high-volume centers, largely due to improved drain management and interventional radiology

PATHOPHYSIOLOGY

1. Enzymatic activation by bile and enteric contents → local tissue digestion
2. Peripancreatic inflammation → fluid collection, abscess formation
3. Erosion of adjacent vessels (especially the gastroduodenal artery stump) → pseudoaneurysm → postpancreatectomy hemorrhage (PPH)
4. Secondary infection → sepsis, multi-organ failure
5. Delayed gastric emptying (DGE) via inflammatory mediator release
6. Fascial dehiscence if fluid tracks to the abdominal wall

RISK FACTORS FOR POPF

ISGPS GRADING SYSTEM

DIAGNOSIS

1. Clinical Suspicion

• Persistent or high-output amylase-rich drain fluid (most reliable early sign)
• Fever and leukocytosis (infection of the fistula/collection)
• Abdominal pain, ileus, or delayed gastric emptying (frequently co-exist; DGE should always prompt a search for underlying POPF as the cause)
• Sentinel bleed (blood in drain or GI bleeding) - suggests pseudoaneurysm from fistula erosion → emergency
• Abdominal distension, peritonism - suggests collection or pancreatic juice peritonitis

2. Drain Fluid Amylase

• Measured on postoperative day 1 and day 3 (routine protocol)
• Drain amylase >3× serum ULN on POD ≥3 = POPF (ISGPS criterion)
• If drain amylase is normal on POD 3-5 and the patient is clinically well, the drains can be safely removed
• Early removal of drains (POD 3) in low-risk cases (low drain amylase, hard pancreas, dilated duct) reduces infectious complications and hospital stay

3. Computed Tomography (CT)

• Clinical deterioration (fever, pain, systemic signs of infection)
• Drain amylase confirms POPF but clinical status is worsening
• Delayed presentation (leak after drain removal)

• Peripancreatic fluid collection around the anastomosis
• Gas within a collection (suggests infection)
• Hematoma or pseudoaneurysm - arterial phase CT (CTA) if bleeding is suspected
• Extent of fluid/collection guides interventional radiology approach

4. MRI/MRCP

• Useful to characterize collections and define anatomy of the main pancreatic duct
• Particularly helpful in planning endoscopic management (transpapillary stenting) by defining duct disruption anatomy

5. Fistulogram / Drain Sinogram

• Contrast injected through the existing drain under fluoroscopy
• Delineates the fistula tract and its communication with the pancreatic duct or anastomosis
• Guides catheter repositioning

MANAGEMENT

1. Adequate drainage of pancreatic secretions (prevents enzymatic tissue destruction)
2. Nutritional support to maintain anabolic state and allow healing

GRADE A (Biochemical Leak)

• No specific intervention required
• Continue routine postoperative care
• Monitor drain output and amylase daily
• Drain removed when amylase normalizes or output becomes clinically insignificant
• Does not affect recovery, length of stay, or overall outcome significantly

GRADE B FISTULA

A. Drainage - Central to Management

• Keep drains in situ and patent; do not remove prematurely
• Upgrade to larger-bore drains if output is thick or collection is enlarging
• Drain position can be adjusted fluoroscopically

• When surgical drains are insufficient or no drain is in the right position
• CT or ultrasound-guided placement of new drains into fluid collections
• Serial upsizing of catheters as needed
• Allows external control of pancreatic juice output
• Multiple drains placed if collections are multilocular

• EUS-guided cystogastrostomy if a mature collection is adjacent to the stomach
• Used when collections are not accessible percutaneously

B. Nutritional Support

• Enteral nutrition preferred over total parenteral nutrition (TPN) - maintains gut integrity, reduces infection, lowers cost
• Nasojejunal (NJ) tube feeds placed distal to the hepaticojejunostomy if oral intake is not tolerated
• NPO or clear liquids may reduce pancreatic stimulation in the short term
• TPN used only when enteral access is not possible

C. Inhibition of Pancreatic Secretion

• Octreotide (100-200 mcg SC TID) or lanreotide - reduce pancreatic exocrine secretion by 50-70% via somatostatin receptor-mediated inhibition
• Multiple RCTs and meta-analyses confirm reduced POPF rates when used prophylactically in high-risk cases in Europe (less clear in US trials)
• Beneficial in reducing fistula volume and accelerating healing
• Duration: typically 5-7 days prophylactically; longer (2-4 weeks) for established Grade B fistula
• Pasireotide (a multi-receptor somatostatin analogue): shown in an RCT to reduce grade B/C POPF incidence when started 1 hour before surgery

D. Antibiotics

• Used when systemic signs of infection are present (fever, leukocytosis, positive drain cultures)
• Broad-spectrum initially (gram-negative and anaerobic coverage); de-escalate based on culture results
• No role for prophylactic antibiotics without evidence of infection

E. Endoscopic Transpapillary Stenting

• For POPF communicating with the main pancreatic duct (confirmed on MRCP or fistulogram)
• ERCP with placement of a transpapillary pancreatic duct stent across the papilla into the main duct
• Diverts pancreatic juice away from the anastomotic disruption and into the duodenum
• Highly effective for partial duct disruptions and communicating fistulas
• Stent typically left for 6-8 weeks then removed

GRADE C FISTULA (Requiring Reoperation)

• Failure of all non-operative measures (persistent high-output fistula, uncontrolled sepsis despite drainage)
• Abdominal catastrophe from pancreatic juice peritonitis
• Postpancreatectomy hemorrhage that cannot be controlled angiographically
• Multi-organ failure attributable to uncontrolled POPF

Surgical Options for Grade C POPF:

• The failed pancreatic anastomosis is taken down and the remaining pancreas is completely resected
• Most definitive solution - eliminates the source of pancreatic juice
• Results in brittle diabetes and permanent exocrine insufficiency (patient requires lifelong insulin + pancreatic enzyme replacement)
• Reserved for uncontrollable Grade C fistulas
• Associated with significant mortality (10-25%) in the emergency setting

• The failed PJ or PG is revised and a new anastomosis is created
• Technically challenging due to inflamed, friable tissue
• Best reserved for cases where the pancreatic remnant is viable and the anastomosis failure is technically correctable

• The fistula tract is anastomosed to a defunctionalized Roux-en-Y jejunal limb, diverting pancreatic juice internally
• Used when the fistula tract is well established and the anatomy allows

• When infected necrosis or uncontrolled sepsis is the primary problem
• Wide drainage with placement of large-bore drains; packing
• May require temporary abdominal closure

• A stent is placed bridging the pancreatic duct to the jejunal lumen to splint the disrupted anastomosis
• Newer technique with limited but promising data

MANAGING THE MOST FEARED CONSEQUENCE: POSTPANCREATECTOMY HEMORRHAGE (PPH)

• Pancreatic enzymes digest the gastroduodenal artery (GDA) stump or adjacent visceral arteries → pseudoaneurysm → rupture
• Sentinel bleed (small episode of drain or GI bleeding preceding catastrophic hemorrhage) is a critical warning sign requiring emergency workup
• Management:
  1. CT Angiography (CTA) first to identify the bleeding source
  2. Angiographic embolization (first-line) - selective coiling of the pseudoaneurysm or the feeding vessel
  3. Surgery if embolization fails: ligation of the vessel, completion pancreatectomy if needed
• Prevention: Mobilization of the falciform ligament and placement over the GDA stump at time of surgery is used by some centers to reduce pseudoaneurysm risk

PREVENTION OF POPF

SUMMARY ALGORITHM

Drain amylase >3× ULN on POD ≥3
         ↓
      POPF Confirmed
         ↓
Clinical assessment: fever? WBC? hemodynamic status? CT?
         ↓                          ↓                         ↓
   Grade A (BL)             Grade B                     Grade C
  (no symptoms)        (clinical impact)            (organ failure /
                                                      reoperation)
         ↓                          ↓                         ↓
 Observe, remove         Keep/upsize drains          Angiography (if
 drains when safe       Antibiotics if infected       hemorrhage)
                        Somatostatin analogues            ↓
                        Nutritional support         If fails → Reoperation:
                        ± Percutaneous drainage     - Completion pancreatectomy
                        ± Endoscopic stenting       - Re-do anastomosis
                        (most resolve)              - Debridement & drainage

KEY POINTS SUMMARY

1. POPF is the most common serious complication after Whipple's procedure (10-30%), defined by drain amylase >3× ULN on POD ≥3
2. Graded A/B/C by ISGPS; only B and C are clinically significant
3. Soft pancreas + small duct = highest risk combination
4. Diagnosis: drain amylase + CT for collections; CTA if bleeding suspected
5. Grade A: conservative/expectant; Grade B: drain management + somatostatin analogues + nutrition + antibiotics ± IR drainage ± endoscopic stenting
6. Grade C: reoperation (completion pancreatectomy is most definitive)
7. PPH is the most lethal consequence - driven by pseudoaneurysm from POPF; sentinel bleed requires emergency CTA and angiographic embolization
8. Most Grade B fistulas resolve without reoperation with appropriate conservative management

Part I: Causes of Surgical Jaundice

Classification

A. MALIGNANT CAUSES (80-90%)

• Cholangiocarcinoma (intrahepatic, perihilar/Klatskin, distal)
• Gallbladder carcinoma

• Pancreatic ductal adenocarcinoma (head of pancreas - most common overall)
• Cystic neoplasms of the pancreas (mucinous cystadenoma/carcinoma, IPMN)
• Pancreatic neuroendocrine tumors (rare)

• Ampullary adenocarcinoma
• Duodenal adenocarcinoma
• Distal bile duct carcinoma

• Hepatocellular carcinoma (with biliary invasion)
• Metastatic disease to the porta hepatis (breast, colon, kidney, stomach, melanoma, lung, germ cell)
• Lymphoma causing biliary compression

B. BENIGN CAUSES (10-20%)

• Choledocholithiasis (common bile duct stones) - most common benign cause
• Mirizzi syndrome (gallstone in Hartmann's pouch compressing CBD externally)

• Chronic pancreatitis (inflammatory mass compressing the CBD)
• Pancreatic pseudocyst (external compression of CBD)
• Primary sclerosing cholangitis (PSC)
• Secondary sclerosing cholangitis (from radiation, ischemia, chemotherapy)
• Recurrent pyogenic cholangitis (biliary strictures with stones)

• Choledochal cyst (types I-V)
• Biliary atresia
• Cystic fibrosis (inspissated secretions)
• Caroli's disease

• Bile duct injury after cholecystectomy (misapplied clips, transection)
• Retained stones after cholecystectomy
• Biliary anastomotic stricture (post-liver transplant, post-hepaticojejunostomy)
• Ischemic biliary stricture

• Cholangitis (ascending, with stricturing)
• Hydatid cyst (echinococcosis)
• Ascaris lumbricoides (biliary ascariasis)
• Liver abscess with biliary compression

• Papillary stenosis / sphincter of Oddi dysfunction
• Ampullary adenoma (benign but causing obstruction)
• Extrinsic compression by lymph node enlargement (benign - tuberculosis, sarcoidosis)

Part II: Periampullary Carcinoma Presenting with Jaundice

DEFINITION AND ANATOMY

CLINICAL FEATURES

1. Jaundice (Cardinal Presenting Feature)

• Progressive, painless obstructive jaundice - the hallmark presentation
• Two-thirds to three-quarters of patients with pancreatic head cancer present with the classic triad: jaundice + pruritus + acholic stools + dark urine
• Jaundice is due to CBD compression or obstruction at the level of the ampulla
• Ampullary, duodenal, and distal bile duct cancers tend to present earlier with jaundice (because even small tumors obstruct the biliary orifice) - hence their higher resectability rates
• Pancreatic head cancers may remain silent until larger, then cause jaundice when the growing tumor compresses the CBD

2. Courvoisier's Sign

• Palpable, non-tender, enlarged gallbladder + jaundice
• Results from progressive, painless biliary obstruction that distends the gallbladder (which is not thickened by scarring as in choledocholithiasis)
• Courvoisier's Law: In a jaundiced patient, a palpable gallbladder is unlikely to be due to gallstones (because chronically inflamed gallbladder in cholelithiasis does not distend), and is more likely to be due to malignant obstruction
• Present in ~25-30% of periampullary cancers

3. Pain

• Contrary to popular teaching, pain frequently occurs with pancreatic cancer
• Early: vague epigastric discomfort or mid-abdominal pain, often described as gnawing or dull
• Characteristic feature: Pain radiating to the back (mid-back, between shoulder blades), classically relieved by leaning forward - indicates retroperitoneal invasion of the celiac plexus
• Severe, unrelenting back pain = advanced disease with celiac plexus invasion (functionally unresectable)
• Ampullary tumors may cause intermittent biliary colic (tumor intermittently prolapsing into and out of the ampullary orifice - "ball-valve" mechanism) causing waxing and waning jaundice

4. Weight Loss and Cachexia

• Common; often profound
• Multifactorial: reduced oral intake, malabsorption (bile/pancreatic duct obstruction), cancer-associated cachexia
• Muscle wasting and loss of visceral fat (cancer-associated cachexia) in advanced disease

5. Other Features

• New-onset diabetes mellitus - destruction of islets; can be an early warning sign
• Steatorrhea - from biliary and pancreatic duct obstruction → malabsorption of fats
• Pruritus - from bile salt deposition in skin (secondary to obstructive jaundice)
• Anorexia, fatigue, malaise - constitutional symptoms of malignancy
• Migratory thrombophlebitis (Trousseau's sign) - in ~10%; procoagulants from tumor necrosis products cause recurrent, migratory superficial thrombophlebitis; Trousseau himself diagnosed his own carcinoma this way
• Duodenal obstruction - late feature; vomiting, gastric outlet obstruction
• GI bleeding - ampullary tumors classically cause occult or frank upper GI bleeding (hematemesis, melena) from tumor erosion into the duodenum; produces silver (tarry) stools in some descriptions

6. Differences Between Subtypes

INVESTIGATIONS

I. Biochemical Tests

• Serum bilirubin - predominantly conjugated (direct) hyperbilirubinemia; typically >3 mg/dL; can reach >20 mg/dL
• Alkaline phosphatase (ALP) - markedly elevated (cholestatic pattern)
• Gamma-glutamyl transferase (GGT) - elevated in parallel with ALP
• ALT/AST - moderately elevated (secondary hepatocellular damage from backpressure)
• PT/INR - may be prolonged (fat-soluble vitamin K malabsorption); corrects with vitamin K injection (confirms obstructive rather than hepatocellular cause)
• Serum albumin - may be low (nutritional compromise in advanced disease)

• CA19-9 - most useful tumor marker; elevated in 70-80% of pancreatic cancers; also elevated in cholangiocarcinoma and other malignancies; falsely elevated in biliary obstruction (any cause); useful for monitoring response to treatment and recurrence (not for screening)
• CEA (carcinoembryonic antigen) - less specific; elevated in ~50%
• CA125 - occasionally elevated

• Anemia (chronic disease, GI blood loss)
• Coagulation screen (PT prolonged → vitamin K malabsorption)
• Blood group and save (pre-operative)

II. Imaging Investigations

• First and most widely available investigation
• Demonstrates: dilated intra- and extrahepatic bile ducts, gallbladder distension (Courvoisier), liver metastases, ascites
• Can identify pancreatic mass in ~60-70% of cases (operator-dependent, limited by bowel gas and obesity)
• Double duct sign on US (dilated CBD + dilated pancreatic duct) is highly suggestive of periampullary malignancy
• Limitation: Cannot reliably visualize the distal CBD or ampullary region; poor for vascular assessment

• Most important single diagnostic and staging modality
• Performed with IV contrast in arterial and venous phases with thin cuts through the pancreas
• Demonstrates:
  • Primary mass (hypodense in pancreatic parenchyma on portal venous phase)
  • Double-duct sign: simultaneous dilation of CBD + main pancreatic duct = virtually diagnostic of periampullary obstruction
  • Extent of tumor, local invasion
  • Vascular involvement: SMA, SMV, portal vein, celiac axis, hepatic artery (determines resectability)
  • Regional lymphadenopathy
  • Distant metastases (liver, peritoneum, lungs)
• 3D CT reconstruction: 95% accurate in determining SMA/SMV involvement; 98% accurate in predicting resectability; 86% accurate in predicting R0 resection
• Criteria for unresectability: Encasement (>180°) of SMA, celiac axis, or hepatic artery; occlusion of SMV/portal vein not amenable to reconstruction; distant metastases; peritoneal carcinomatosis

• Excellent for biliary/pancreatic ductal anatomy without radiation or contrast
• MRCP: non-invasive visualization of the entire biliary tree and pancreatic duct
• MRI: superior to CT for characterizing soft-tissue extent, detecting small liver metastases, and delineating ductal involvement
• MRA (with gadolinium): assesses vascular anatomy in a single session
• Combined MRI + MRCP + MRA can provide tumor extent, ductal anatomy, and vascular anatomy non-invasively
• Preferred in patients with contrast allergy or renal impairment

• Highly accurate for small tumors not visible on CT/MRI
• Allows simultaneous FNA (fine-needle aspiration) for tissue diagnosis
• Accurate for T-staging and assessment of locoregional vessels
• Limitation: Poor for distant metastases; operator-dependent; tends to over-call vascular involvement in borderline cases

• Classic findings of pancreatic cancer: Abrupt cutoff of the main pancreatic duct + distal dilation; "double duct sign" = cutoff of both pancreatic duct and CBD at the level of the genu
• Long, irregular stricture of the CBD in distal bile duct cancer
• Therapeutic roles:
  • Biliary stenting for jaundice relief (palliation or bridge to surgery)
  • Tissue biopsy via brushings/forceps biopsy of biliary stricture
  • Sphincterotomy
• Diagnostic ERCP alone is rarely required now given modern CT/MRI capability
• Indications: Biliary obstruction + cholangitis requiring emergency decompression; when CT/MRI is equivocal but clinical suspicion is high

• Invasive; defines biliary anatomy above the obstruction
• Allows external biliary drainage (PBD) if ERCP fails or is not feasible
• Used when ERCP is not possible or fails
• Complications: bleeding, hemobilia, bile leak

• Evolving role; can identify CT-occult primary tumors in patients with unexplained jaundice
• Useful for detecting distant metastases and differentiating benign from malignant lesions
• Not standard of care for initial staging

• Used selectively at high-volume centers before planned resection
• Identifies small liver metastases and peritoneal carcinomatosis not seen on CT (occult M1 disease)
• Avoids unnecessary laparotomy in 5-10% of patients who appear resectable on CT
• Highest yield for body/tail tumors and uncinate tumors (more likely to have occult metastases)
• Intraoperative splanchnicectomy can be performed for pain palliation

III. Tissue Diagnosis

• Not required before curative resection in a surgically fit patient with a resectable mass + clinical picture of malignancy
• "Jaundice + weight loss + pancreatic mass/biliary stricture = carcinoma until proven otherwise"
• Preoperative biopsy required when:
  • Planned neoadjuvant chemotherapy
  • Patient unfit for surgery (tissue needed before palliative chemotherapy/RT)
  • Lesion deemed unresectable
  • Atypical features raising possibility of lymphoma, autoimmune pancreatitis, or metastatic disease
  • Clinical trial enrollment
• Biopsy methods: EUS-FNA (preferred); CT-guided FNA; ERCP brushings/forceps biopsy
• A negative biopsy does not exclude malignancy (due to desmoplastic stroma in PDAC) - a well patient with a resectable lesion should still proceed to surgery

MANAGEMENT

A. PRE-OPERATIVE ASSESSMENT AND OPTIMIZATION

• CT-defined resectability criteria used (NCCN classification: resectable, borderline resectable, locally advanced, metastatic)
• Resectable: No arterial involvement; patent SMV/portal vein
• Borderline resectable: Short-segment SMV/portal vein abutment; hepatic artery abutment amenable to reconstruction; SMA abutment ≤180°
• Locally advanced (unresectable): SMA/celiac encasement >180°; aortic invasion; unreconstructable venous occlusion

• Vitamin K injection (10 mg IM/IV for 3 days) to correct coagulopathy from fat-soluble vitamin malabsorption
• Nutritional support - high-protein diet, oral nutritional supplements, consider parenteral nutrition if severe malnutrition
• Preoperative biliary drainage (PBD):
  • Controversial - not routinely recommended in resectable tumors (increases infection risk)
  • Indicated in: cholangitis, severely impaired hepatic function, planned neoadjuvant therapy, prolonged surgical delay (>2 weeks), total bilirubin >15 mg/dL with impending renal failure
  • Performed by ERCP stenting (preferred) or PTC

B. SURGICAL MANAGEMENT (CURATIVE INTENT)

• Removes the head of the pancreas, entire duodenum, distal CBD, gallbladder, and distal stomach (classic) or proximal 2-3 cm of duodenum with pylorus preserved (PPPD)
• Three reconstruction anastomoses: Pancreaticojejunostomy + Hepaticojejunostomy + Gastrojejunostomy (or duodenojejunostomy in PPPD)
• Portal/SMV resection may be performed when tumor involves these vessels (vascular reconstruction with patch or interposition graft)
• Lymphadenectomy: standard D2 regional nodal dissection; ≥12 nodes recommended

• Free (negative) margins: pancreatic neck, uncinate/posterior margin (SMA margin), bile duct
• The SMA margin (uncinate/retroperitoneal margin) is the most common site of positive margin in PDAC
• R0 resection is the single most important prognostic factor

• Operative mortality: 2-3% (dramatically improved from 20-40% historically)
• Morbidity: ~40% (most common: POPF, delayed gastric emptying, wound infection)

C. NEOADJUVANT AND ADJUVANT THERAPY

• Standard for borderline resectable disease: FOLFIRINOX or gemcitabine + nab-paclitaxel chemotherapy ± radiation
• Goal: downstage tumor to achieve R0 resection
• Growing evidence for neoadjuvant treatment in resectable disease too (allows patient selection, targets micrometastases early)

• All resected patients should receive adjuvant chemotherapy
• Modified FOLFIRINOX (mFOLFIRINOX) for 6 months: current standard in fit patients; improves median OS to ~54 months (PRODIGE 24 trial)
• Gemcitabine + capecitabine: alternative; ESPAC-4 trial showed benefit over gemcitabine alone
• Adjuvant radiation therapy: not standard in Europe; used selectively in North America for node-positive or positive-margin cases

D. PALLIATIVE MANAGEMENT (UNRESECTABLE / METASTATIC)

• ERCP + endoscopic stent placement (preferred): self-expanding metal stent (SEMS) for life expectancy >3-6 months; plastic stent for shorter prognosis
• Percutaneous transhepatic biliary drainage (PTBD) if ERCP fails
• Surgical bypass (hepaticojejunostomy) if laparotomy is performed and obstruction is confirmed intraoperatively

• Endoscopic duodenal stent (duodenal SEMS)
• Surgical gastrojejunostomy (bypass) - laparoscopic or open; provides more durable relief

• Oral analgesics (WHO ladder: paracetamol → NSAIDs → opioids)
• Celiac plexus neurolysis (CPN): Chemical ablation with absolute alcohol; provides superior pain relief compared to opioids alone; performed EUS-guided or CT-guided
• Surgical chemical splanchnectomy: Intraoperative injection of absolute alcohol into celiac ganglia if laparotomy is performed

• FOLFIRINOX (5-FU, leucovorin, irinotecan, oxaliplatin): First-line in fit patients; median OS ~11.1 months (PRODIGE 4/ACCORD 11 trial)
• Gemcitabine + nab-paclitaxel: Alternative; median OS ~8.5 months (MPACT trial)
• Gemcitabine monotherapy: For unfit patients
• Targeted therapy: PARP inhibitors (olaparib) for BRCA1/2-mutated tumors (maintenance); pembrolizumab for MSI-H/dMMR tumors (~1%)

Key Points

1. Periampullary carcinoma arises from four structures at the ampulla of Vater: pancreatic head, ampulla, distal CBD, or periampullary duodenum - requiring pancreaticoduodenectomy for all
2. Progressive painless jaundice + Courvoisier's sign + weight loss = periampullary carcinoma until proven otherwise
3. CT (pancreatic protocol) is the definitive staging investigation; the double-duct sign is virtually diagnostic
4. EUS-FNA provides tissue diagnosis for neoadjuvant or palliative treatment planning
5. Tissue biopsy is NOT required before curative resection in a fit patient with resectable disease
6. Whipple's procedure at a high-volume center offers the only chance of cure; R0 resection is the critical prognostic determinant
7. Ampullary carcinomas have the best prognosis among periampullary cancers; PDAC the worst
8. For unresectable disease: biliary stenting + systemic chemotherapy (FOLFIRINOX/GnP) + pain management with celiac plexus neurolysis